DELSOL Avocats has advised the AGORiA Santé consortium, in partnership with BIOGROUP, on obtaining the CNIL’s (French data protection authoritys) first authorization to combine biology and SNDS (French national health data system) data in a health data warehouse.
Created in 2021, the AGORIA Santé consortium comprises AstraZeneca France, Takeda France, Impact Healthcare and Docaposte, its lead partner. It is implementing a health data warehouse with the ambition, within a secure legal and technical framework based on shared governance, to offer Real Life Health Data (RHLD) to public and private players to carry out research, study or evaluation projects.
The new CNIL authorization obtained by the AGORiA Santé consortium marks a turning point for the health data platform. For the first time, databases combining data from the SNDS and the results of patients’ biological analyses on major public health issues will be created, to answer a wide range of scientific questions requiring the mobilization of medical biology results (tumor biomarkers, blood metabolites, hormone assays, etc.).
BIOGROUP, France’s leading medical biology network, which carries out around a quarter of all outpatient analyses in France, will share pseudonymized patient data from its medical analysis activities in the AGORiA Santé repository, in line with the scientific purpose for which they are to be used. Linked to the SNDS via the AGORiA Santé feeder system, this data can be used by project sponsors (industry, academia) as part of a number of predefined research programs.
The first data linked to the SNDS should be available by the end of 2026.
DELSOL Avocats assisted AGORiA Santé in obtaining this authorization from the CNIL, with a team including Jeanne Bossi Malafosse, partner, Aura Braun, associate. DELSOL Avocats has been advising the Agoria Santé consortium since its setting up in 2021 on personal and health data issues, in particular for the implementation of the Agoria Santé health warehouse.

